Fig. 1: Aberrant upregulation of LONP1 is associated with poor clinical outcomes in patients with PCa.
From: Lon protease 1-mediated metabolic reprogramming promotes the progression of prostate cancer
A–D LONP1 expression of patients with PCa from TCGA database. A LONP1 expression in PCa was higher than that in matched adjacent non-cancerous tissues. B LONP1 was aberrantly overexpressed in PCa tumor tissues compared to normal tissues. C Upregulated expression of LONP1 was significantly associated with Gleason Score. D Survival probability based on LONP1 expression in PCa. LONP1 high (red) group corresponds to the fourth quartile of expression, while LONP1 low (blue) group corresponds to the first quartile. E Scatterplot showing the correlation between LONP1 expression and epithelial–mesenchymal transition (EMT) score across four different PCa study cohorts, based on Bayer et al.’s work. Spearman correlation coefficient and P value are marked. F A full view of the immunohistochemistry staining of LONP1 in the PCa tissue microarray (tumor tissues, n = 97; adjacent nontumor tissues, n = 5). G–I Representative images showing immunohistochemistry staining of LONP1 in benign prostate/PCa tissues (G), PCa tissues at different pathological stages (H), as well as PCa tissues with Gleason Score > 7 compared with those with Gleason Score ≤ 7 (I). The plots show the mean value for each immunoreactivity score (IRS) with statistical evaluation. Scale bar, up: 250 μm; down: 50 μm. Data were shown as mean ± SEM. **P < 0.01; ***P < 0.001.
